nations life sciences firms report progress with the fda yet significant challenges still exist

The nation’s pharmaceutical, biotechnology and medical device companies report that the U.S. Food and Drug Administration (FDA) has made progress with improved guidance, expectations and approvals, but the industry remains concerned about a number of regulatory challenges.A national report issued today outlines a series of issues that still need to be resolved to improve product review delays and shorten the approval process via user fees.